CHAIN features in Genetic Engineering & Biotechnology News (GEN)
”An expansive view of design has been adopted at CHAIN Biotechnology, which is developing new therapeutics based on living microbes where the “bug is the drug.” These drugs are based on a single strain of Clostridium bacteria that is naturally found in the gut, but which has been deliberately engineered to carry a therapeutic payload, such as […]
CHAIN sponsor Nottingham student Biotech Ambassador Award
CHAIN has worked closely with the University of Nottingham since our beginning, and it is our pleasure to announce Anastasiya Buryak the winner of the CHAIN Biotechnology Award for Best Student Ambassador for Biotech and Best Academic Performance. CHAIN attended the award ceremony last week at the University’s Sutton-Bonnington Campus and we caught up with […]
Cancer vaccine firm Oxford Vacmedix announces collaboration & Innovate UK grant
Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK grant to CHAIN Biotechnology Ltd (CHAIN) and the University of Oxford to develop live biotherapeutics that support oral delivery for OVM’s recombinant overlapping peptide (ROP) […]
Superior and effective microbiome therapeutics
About us
CHAIN Biotechnology Ltd is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases.
Platform
Our Clostridium Assisted Drug Development (CADD™) platform provides superior gut delivery to support a pipeline of drug candidates addressing multiple therapeutic areas associated with the gut microbiome.
Clinical Focus
We target inflammatory bowel disease with a focus on Ulcerative Colitis. Our lead drug candidate is a live biotherapeutic engineered to produce anti-inflammatory metabolites; β-hydroxybutyrate and butyrate.